Treatment of chronic myelogenous leukemia with the tyrosine kinase inhibitor STI571 results in marked regression of bone marrow fibrosis. [electronic resource]
Producer: 20020128Description: 381-3 p. digitalISSN:- 0006-4971
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Agents -- therapeutic use
- Benzamides
- Biopsy
- Bone Marrow -- pathology
- Enzyme Inhibitors -- therapeutic use
- Erythropoiesis
- Female
- Granulocytes -- pathology
- Hematopoiesis
- Humans
- Imatinib Mesylate
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive -- drug therapy
- Male
- Megakaryocytes -- pathology
- Middle Aged
- Piperazines -- therapeutic use
- Primary Myelofibrosis -- drug therapy
- Protein-Tyrosine Kinases -- antagonists & inhibitors
- Pyrimidines -- therapeutic use
- Remission Induction
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.